Evaluating Riociguat in the Treatment of Pulmonary Arterial Hypertension: A Real-World Perspective.

Vasc Health Risk Manag · 2022 · PMC9590350 · PMID 36299800

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

showed a trendno p-value reported

Despite this disappointment, patients receiving riociguat showed a trend towards reduction in digital ulcerations and an improvement in Raynaud’s phenomena.

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.